Clinical Trial Update: Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for intra-arterial Lutetium-177-dotatate in neuroendocrine tumor patients with liver metastases (Phase 2 and Phase 3) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Metastases
• Neuroendocrine Tumor

Drugs mentioned

• Lutetium-177 dotatate (Lutetium-177 dotatate)

Snippet

Sponsor: Marnix Lam | Conditions: Neuroendocrine Tumors, Liver Metastases | Phase 2, Phase 3 | Status: COMPLETED